Search

Your search keyword '"Banasiak, W."' showing total 588 results
Start Over Author "Banasiak, W."
588 results on '"Banasiak, W."'

1. The beneficial effects of adherence to outpatient telecare intervention on clinical outcomes after an episode of acute heart failure: insights from the prospective randomised controlled AMULET trial

Author

Krzesinski, P, primary, Galas, A, additional, Piotrowicz, K, additional, Chrom, P, additional, Jankowska, E A, additional, Siebert, J, additional, Stanczyk, A, additional, Siwolowski, P, additional, Gutknecht, P, additional, Szalewska, D, additional, Banasiak, W, additional, Ponikowski, P, additional, and Gielerak, G, additional

Published
2023
Full Text
View/download PDF

5. Health locus of control and the sense of self-efficacy in patients with systolic heart failure: a pilot study

Author

Rydlewska A, Krzysztofik J, Libergal J, Rybak A, Banasiak W, Ponikowski P, and Jankowska EA

Subjects
Medicine (General), R5-920
Abstract

Agnieszka Rydlewska,1,2 Justyna Krzysztofik,3 Julia Libergal,3 Agata Rybak,3 Waldemar Banasiak,1 Piotr Ponikowski,1,2 Ewa A Jankowska1,21Centre for Heart Diseases, Department of Cardiology, Military Hospital, Wroclaw, Poland; 2Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland; 3Student’s Scientific Organization, Laboratory for Applied Research on Cardiovascular System, Wroclaw Medical University, Wroclaw, PolandBackground: Treatment of heart failure (HF) requires the lifelong adherence to medical self-care regimes. The objective of this study was to examine health-control beliefs and the sense of self-efficacy (psychological features particularly important for efficient compliance among patients suffering from chronic diseases) in patients with systolic HF in relation to clinical status and depressive symptoms.Subjects and methods: Sixty-six consecutive patients with chronic systolic HF, hospitalized in the Centre for Heart Diseases, Military Hospital (94% men, age: 61 ± 11 years, ischemic etiology: 63%, left ventricular ejection fraction: 32% ± 12%), filled in (during their hospital stay): (1) the Multidimensional Health Locus of Control Scale measuring three possible localizations of health control: “internality” (ie, the belief that health status depends only on personal decisions and behaviors); “powerful others externality” ([PHLC subscale] ie, the conviction that health depends on “powerful people” such as doctors, family members, close friends), and “chance externality” (ie, belief that health status is determined by chance, fate, or luck), and (2) the Generalized Self-Efficacy Scale. The results obtained by HF patients were compared to those reported by patients with other chronic diseases and healthy subjects.Results: In patients with HF, internality was similar to values obtained by patients with diabetes, men after myocardial infarction, and women after mastectomy; and was lower than in healthy subjects. Powerful others externality was more pronounced in patients with HF as compared to other groups of patients and healthy people. Only women after mastectomy had higher scores of PHLC. In patients with HF, chance externality was similar to values reported in patients with renal failure, men after myocardial infarction, and women after mastectomy; and was less pronounced than in healthy subjects. The majority (77%) of patients with HF were characterized by a high sense of self-efficacy (>the 7th sten score), having the highest sense of self-efficacy among patients with other chronic diseases and healthy controls. Higher internality was accompanied by higher sense of self-efficacy (P < 0.05) in patients with HF. Subjects with high plasma N-terminal pro-B type natriuretic peptide (reflecting the disease severity) had the least pronounced internality (P < 0.05), whereas those with more advance depressive symptoms had the lower sense of self-efficacy (P = < 0.05).Conclusion: Patients with systolic HF demonstrate a conviction that other people, including physicians, have a large influence on their health status, and at the same time are aware of the efficacy of their own activities in coping with the disease. Such a configuration of psychological features seems to be beneficial in the context of the developing modern strategies, which due to the improved cooperation between the physicians and the patients could enhance the compliance in patients with HF.Keywords: health locus of control, self-efficacy, heart failure, compliance, depressive symptoms

Published
2013

15. P754Iron status indices (transferrin saturation, serum ferritin) in the course of acute myocarditis: relations with neurohormonal activation, cardiac dysfunction and clinical recovery

Author

Franczuk, P, primary, Kosiorek, A, additional, Tkaczyszyn, M, additional, Drozd, M, additional, Zapolska, A, additional, Walczak, T, additional, Kulej-Lyko, K, additional, Sidorowicz, N, additional, Soltowska, A, additional, Banasiak, W, additional, Kosmala, W, additional, Przewlocka-Kosmala, M, additional, Jaroch, J, additional, Ponikowski, P, additional, and Jankowska, E A, additional

Published
2019
Full Text
View/download PDF

16. P920The influence of iron status on the impaired functioning of human cardiofibroblasts and cardiomyocytes in the course of acute phase of myocarditis

Author

Kobak, K A, primary, Dziegala, M, additional, Franczuk, P, additional, Kasztura, M, additional, Tkaczyszyn, M, additional, Drozd, M, additional, Josiak, K, additional, Sidorowicz, N, additional, Gac, P, additional, Kiczak, L, additional, Bania, J, additional, Banasiak, W, additional, Ponikowski, P, additional, and Jankowska, E A, additional

Published
2018
Full Text
View/download PDF

18. P3195Impaired functioning and low mass of skeletal muscles in men with heart failure with reduced ejection fraction are reflected by reduced muscle-derived irisin

Author

Kasztura, M, primary, Dziegala, M, additional, Kobak, K A, additional, Tkaczyszyn, M, additional, Drozd, M, additional, Wegrzynowska-Teodorczyk, K, additional, Josiak, K, additional, Bania, J, additional, Kiczak, L, additional, Banasiak, W, additional, Ponikowski, P, additional, and Jankowska, E A, additional

Published
2018
Full Text
View/download PDF

19. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

Author

James, Wp, Caterson, Id, Coutinho, W, Finer, N, VAN GAAL LF, Maggioni, Ap, TORP-PEDERSEN, C, Sharma, Am, Shepherd, Gm, Rode, Ra, Renz, Cl, Van Gaal LF, Torp-Pedersen, C, Pepine, C, Pocock, S, Drexler, H, Swedberg, K, Sleight, P, Armstrong, P, Kerr, D, Dagenais, G, Brophy, J, Avezum, A, Bogaty, P, Fabbri, G, Galli, M, Hildebrandt, P, Mann, J, Ostergren, J, Sherman, D, Zannad, F, Colquhoun, D, Hollanders, G, e Forti A, Costa, Cifkova, R, Toubro, S, Ziegler, O, Scherbaum, Wa, Jordan, J, Halmy, L, Ferrannini, E, Santini, F, Gonzalez, C, Narkiewicz, K, Hancu, N, Payer, J, Pascual, J, Wilding, J, Campbell, L, Carey, D, Gerstman, M, Karrasch, J, Lefkovits, J, Marks, J, Marks, S, Moses, R, Phillips, P, Proietto, J, Roberts, D, Roberts-Thomson, P, Shaw, J, Simpson, R, Singh, B, Singleton Jeffries, W, Stuckey, B, Boland, J, Brohet, C, Coucke, F, Dendale, P, Jouret, G, Kolanowski, J, Kutnowski, M, Martens, F, Muls, E, Peiffer, F, Penninckx, H, Scheen, A, Schoors, D, Vaerenberg, M, Van Cleemput, J, Van Crombrugge, P, Van Kuyk, M, Verhaegen, A, Wollaert, B, de Albuquerque DC, Appolinario, J, de Godoy Matos AF, Gross, Jl, Halpern, A, Kerr Saraiva JF, Milagres, R, Repetto, G, Suplicy, Hl, Zanella, Mt, Bednarova, J, Cepelak, V, Cerny, P, Hainer, V, Havranek, P, Homza, M, Jansa, P, Karlicek, M, Kolesar, J, Kotik, I, Kucera, D, Kuchar, J, Kunc, M, Kvapil, M, Linhart, A, Machova, V, Matuska, J, Oral, I, Pavlas, J, Pesatova, S, Povolny, J, Semrad, B, Smetana, K, Soucek, M, Svacina, S, Tesinsky, P, Urbanek, R, Wasserburger, B, Zachoval, R, Zahumensky, E, Zidkova, E, Astrup, A, Dominguez, H, Faber, J, Hilderbrant, P, Kober, L, Perrild, H, Richelsen, B, Sogaard, P, Svendsen, Ol, Urhammer, S, Archambeaud, F, Basdevant, A, Borys, Jm, Bringer, J, Brunetiere, C, Charpentier, G, Cocaul-André, M, Dabadie, H, Dubreuil, A, Estour, B, Gautier, Jf, Gibault, T, Halimi, S, Hespel, Jp, Issa Sayegh, M, Krempf, M, Laville, M, Lecerf, Jm, Louvet, Jp, Penfornis, A, Ritz, P, Schlienger, Jl, Schmitt, B, Valensi, P, Baar, M, Beermann, J, Bock, M, Boenner, G, Dammann, Hg, Diehm, C, Ditschuneit, H, Gadow, J, Gehlhar, S, Gessner, S, Guthersohn, A, Hamann, A, Hanefeld, M, Hasenfuss, G, Herzner, A, Heun, Kc, Heufelder, Ae, Hohensee, H, Jacob, S, Krings, P, Krätzig, B, Krosse, B, Lehmann, Rt, Mindt-Prüfert, S, Maisch, B, Pfeiffer, Af, Richard, F, Rose, B, Schmidt, E, Scholze, J, Schreckenberg, A, Stuebler, P, Walter, J, Wirth, A, Wunderlich, J, Abraham, G, Altorjay, A, Augusztin, G, Csaszar, A, Czuriga, I, Dinnyes, J, Gero, L, Gyimesi, A, Janosi, A, Kovacs, I, Liziczai, I, Majtenyi, A, Medvegy, M, Nadhazi, Z, Pados, G, Polak, G, Ronaszeki, A, Sido, Z, Simon, K, Anzà, C, Bevilacqua, M, Bosello, O, Chiariello, M, Cordera, R, Ferrari, E, Frittitta, L, Giorgino, R, Liuzzi, A, Malinverni, C, Di Mario, U, Melchionda, N, Occhi, G, Perticone, F, Pinchera, A, Pinelli, G, Rovera, G, Santeusanio, F, Urbinati, S, Alpizar-Salazar, M, Carrillo-Ortega, E, Fanghanel Salmon, G, Laviada-Molina, Ha, Madero, Ma, Rodriguez, G, Saldate, C, Sanchez-Castillo, Cp, Violante, Rm, Wacher, N, Zayas-Jaime, Fj, Zuniga-Guajardo, S, Adamiec, R, Banasiak, W, Chrusciel, P, Derlaga, B, Gebala, A, Gessek, J, Janik, K, Janion, M, Kalina, Z, Kozlowski, A, Kusnierz, B, Majcher, Z, Miekus, P, Niegowska, J, Okopien, B, Ostrowska, L, Pasowicz, M, Piepiorka, M, Pluta, W, Polaszewska-Muszynska, M, Ponikowski, P, Pupek-Musialik, D, Sawicki, A, Sobocik, H, Stankiewicz, A, Szpajer, M, Trojnar, R, Tykarski, A, Wrabec, K, Wyrzkowski, B, Zahorska-Markiewicz, B, Zalewski, M, Carrageta, M, Mendes Pedro MM, Parente Martins LM, dos Santos, L, Babes, A, Creteanu, G, Dan, Ga, Dragulescu, Si, Graur, M, Tirgoviste, Ci, Morosanu, M, Mota, M, Paveliu, Fs, Radoi, M, Ranetti, A, Totoian, I, Andre, I, Bugan, V, Cencarik, J, Csala, L, Farsky, S, Gonsorcik, J, Kamensky, G, Kmec, J, Krahulec, B, Kurian, R, Macek, V, Majercak, I, Micko, K, Mokan, M, Riecansky, I, Sojka, G, Uhliar, R, Urgeova, L, Vancik, J, Baro, Fm, Barrios Merino, A, Borras, Jl, Caixas, A, Cuatrecasas Cambra, G, Dominguez Escribano JR, Duran Garcia, S, Escobar-Jimenez, L, Esteva de Antonio, I, Formiguera Sala, X, Garcia-Luna, Pp, Garcia Robles, R, Gonzalez Albarran, O, Hernandez-Mijares, A, Martin Hidalgo, A, Masmiquel Comas, L, Morales Perez, F, Moreno Esteban, B, Pascual Izuel JM, Redon Mas, J, Ricart, W, Rubio, Ma, Ruilope, Lm, Salas-Salvado, J, Terroba Larumbe, M, Tinahones, F, de la Torre Casares ML, Vidal Cortada, J, Zuniga-Perez Lemaur, M, Abdulhakim, Ee, Adler, A, Barnett, Ah, Bodmer, C, Campbell, Iw, Chowdhury, T, Cleland, J, Cook, Rc, Dinneen, S, Donnachie, H, Haslam, Dw, Hillis, Gs, Horne, M, Howarth, Dj, Hughes, E, Jackson, S, Jones, Sc, Jones, Th, Kumar, S, Lean, M, Maroni, J, Mcinnes, G, Middleton, A, Morris, A, Newcombe, G, O'Kane, Kp, Pavel, Ic, Pawa, R, Perry, C, Pitts, C, Raja, A, Reckless, J, Robinson, J, Sarmiento, R, Soo, Sc, Taylor, S, Thomas, Ho, Thomson, Ma, and Wilkins, M.

Subjects
Male, medicine.medical_specialty, Myocardial Infarction, Blood Pressure, Kaplan-Meier Estimate, Type 2 diabetes, Klinikai orvostudományok, Placebo, law.invention, Double-Blind Method, Randomized controlled trial, Weight loss, law, Internal medicine, Appetite Depressants, medicine, Humans, Obesity, Myocardial infarction, Stroke, Aged, business.industry, Hazard ratio, Orvostudományok, General Medicine, Middle Aged, Overweight, medicine.disease, Surgery, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Cardiology, Female, Human medicine, medicine.symptom, business, Cyclobutanes, Sibutramine, medicine.drug
Abstract

Background The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. Methods We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). Results The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. Conclusions Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)

Published
2010
Full Text
View/download PDF

27. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure

Author

Jankowska, E. A., primary, Kasztura, M., additional, Sokolski, M., additional, Bronisz, M., additional, Nawrocka, S., additional, Ole kowska-Florek, W., additional, Zymli ski, R., additional, Biegus, J., additional, Siwo owski, P., additional, Banasiak, W., additional, Anker, S. D., additional, Filippatos, G., additional, Cleland, J. G. F., additional, and Ponikowski, P., additional

Published
2014
Full Text
View/download PDF

28. Ferric carboxymaltose in patients with heart failure and iron deficiency

Author

Anker, S D, Comin Colet, J, Filippatos, G, Willenheimer, R, Dickstein, K, Drexler, H, Lüscher, T F, Bart, B, Banasiak, W, Niegowska, J, Kirwan, B A, Mori, C, von Eisenhart Rothe, B, Pocock, S J, Poole-Wilson, P A, Ponikowski, P, Anker, S D, Comin Colet, J, Filippatos, G, Willenheimer, R, Dickstein, K, Drexler, H, Lüscher, T F, Bart, B, Banasiak, W, Niegowska, J, Kirwan, B A, Mori, C, von Eisenhart Rothe, B, Pocock, S J, Poole-Wilson, P A, and Ponikowski, P

Abstract

BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chro

Published
2009

34. Iron status in patients with chronic heart failure

Author

Jankowska, E. A., primary, Malyszko, J., additional, Ardehali, H., additional, Koc-Zorawska, E., additional, Banasiak, W., additional, von Haehling, S., additional, Macdougall, I. C., additional, Weiss, G., additional, McMurray, J. J. V., additional, Anker, S. D., additional, Gheorghiade, M., additional, and Ponikowski, P., additional

Published
2012
Full Text
View/download PDF

37. 'Iron deficiency: an ominous sign in patients with systolic chronic heart failure' [Eur Heart J 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]

Author

Jankowska, E. A., primary, Rozentryt, P., additional, Witkowska, A., additional, Nowak, J., additional, Hartmann, O., additional, Ponikowska, B., additional, Borodulin-Nadzieja, L., additional, Banasiak, W., additional, Polonski, L., additional, Filippatos, G., additional, McMurray, J. J. V., additional, Anker, S. D., additional, and Ponikowski, P., additional

Published
2011
Full Text
View/download PDF

38. Iron deficiency: an ominous sign in patients with systolic chronic heart failure

Author

Jankowska, E. A., primary, Rozentryt, P., additional, Witkowska, A., additional, Nowak, J., additional, Hartmann, O., additional, Ponikowska, B., additional, Borodulin-Nadzieja, L., additional, Banasiak, W., additional, Polonski, L., additional, Filippatos, G., additional, McMurray, J. J. V., additional, Anker, S. D., additional, and Ponikowski, P., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results